Independent Education Symposium

BCMA-targeted therapies in myeloma: The new treatment frontier

Thursday 23rd May 2024 – 08:30-10:00 CEST

08:30 Welcome and introduction: Targeting BCMA in MM
Mohamad Mohty
Where do we stand with the different modalities of therapy?
08:35 Anti-BCMA bispecific antibodies
Saad Usmani
08:55 Anti-BCMA ADCs
Rakesh Popat
09:15 Anti-BCMA CAR-T cells
Suzanne Lentzsch
09:35 Discussion and audience Q&A
09:45 Closing
Mohamad Mohty

Learning Objectives

After participating in this program, learners will be able to:

  • Explain the different BCMA-targeting strategies for patients with MM
  • Evaluate the latest clinical data available for these therapies and their implications for clinical practice
  • Assess challenges and remaining needs for the future of myeloma therapy


Mohamad Mohty

Sorbonne University, Hôpital Saint-Antoine, Paris

Dr Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris.

Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the past chairman of the Acute Leukemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).

In addition to publishing more than 900 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International.

Rakesh Popat

University College Hospital, London, UK

Rakesh Popat is a Consultant Haematologist at University College Hospital and Associate Professor at University College London with a specialist interest in Multiple Myeloma. He leads the myeloma clinical trials program and is the Cancer Program lead for the National Institute for Health Research (NIHR) University College London Hospitals Clinical Research Facility. Dr. Popat completed his PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana-Farber Cancer Institute in Boston, MA, USA.

Dr. Popat is the Chair of the UK Myeloma Research Alliance (UKMRA), a member of the executive board of the UK Myeloma Society (UKMS) and the Young board of the European Myeloma Network (EMN). In addition, he is a member of the International Myeloma Working Group (IMWG) where he contributes to research and guidelines and the Principle Investigator for the NIHR Myeloma Health Informatics Collaborative.

He is the Chief Investigator on many myeloma clinical trials and is particularly involved in the development of novel treatments, including T cell immunotherapies and new antibody approaches.

Suzanne Lentzsch

Columbia University, USA

Dr. Lentzsch is a Professor of Medicine and the Director of Multiple Myeloma and Amyloidosis Service at Columbia University Medical Center, New York. Her translational research identifies novel targets for treating MM, MM bone disease, and AL amyloidosis. In a series of multicenter clinical trials, she established bendamustine as a new treatment for relapsed amyloidosis. In an FDA-funded, first-in-human phase 1 trial, she studied the monoclonal antibody 11-1F4 (Cael-101) that targets amyloid fibrils. Based on her work Caelum Biosciences was founded, and Cael-101 is currently being tested in a phase 3 trial.

Dr. Lentzsch is Co-Chair of the NCI Myeloma Steering Committee, a member of ASH Scientific Committee for Plasma Cell Neoplasia, the Educational and Steering Committee for the Society of Hematology and Oncology, and the SWOG Myeloma Working Group. She co-chairs the Career Development Committee of the International Myeloma Society. She is Associate Editor for JCO and on the Editorial Board for Blood Cancer Discoveries.

Dr. Lentzsch’s translational research received grant support from the NCI, FDA, Pennsylvania Department of Health, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Cancer Research Institute, Emerson Collect Fund, and International Myeloma Society. Dr. Lentzsch has published over 140 original articles, editorials, and chapters, many as lead or senior author, in high-impact journals such as JCI, JCO, Blood, Cancer Research, and Leukemia.

Saad Usmani

Memorial Sloan Kettering Cancer Center, USA

Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut.

He joined the Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences in Little Rock, AR in 2010 as the Director of Developmental Therapeutics. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies where he built an internationally renowned myeloma program. He joined Memorial Sloan Kettering Cancer Center in 2021 as the Chief of Myeloma Service and hold a faculty position as Professor of Clinical Medicine at Weill Cornell Medical College, Cornell University.

Dr. Usmani is board-certified in internal medicine, medical oncology, and hematology. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the ALLIANCE Myeloma Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology, International Myeloma Society (Board Member), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the Vice-Chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Plasma Cell Disorders.

He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, and the LLS CDP Achievement Award. Dr. Usmani has authored/co-authored more than 270 peer-reviewed research manuscripts (NEJM, Lancet, JCO, Cancer Cell, Blood, Leukemia, etc.).  Active in clinical and translational research, Dr. Usmani has research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma.


This symposium has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH) CME Unit. The EBAH-CME Unit has approved this educational activity for:

1 EBAH credit points

Each physician should only claim credits for time that she/he actually spent in the educational activity.

All participants may print a European Board for Accreditation in Hematology (EBAH) CME certificate indicating the number of EBAH-CME Credit Points awarded, directly from the system on the CME section of the EBAH website at (

How to collect your EBAH-CME credit points:

  • Visit our website:
  • Create a professional account: simple and free of cost
  • Complete the short evaluation form at the end of the symposium and select the option to receive CME credits

Within the EBAH-CME system you can:

  • Print your EBAH-CME certificates
  • Review and manage your personal account
  • Search for accredited events based on the European Hematology Curriculum

For further assistance please contact:
Email: [email protected]
Tel: +31 70 3020 099


This educational activity is supported by an educational grant from GlaxoSmithKline.